Are you eligible for targeted therapy?

helps inform patient management related to the PARP inhibitors Lynparza™ and Zejula™

BRACAnalysis CDx helps inform patient management related to the PARP inhibitors Lynparza (olaparib) and Zejula™ (niraparib). It is the only FDA-approved laboratory developed test approved to be used to inform treatment decisions for the PARP inhibitor, Lynparza. A positive BRACAnalysis CDx result in patients with ovarian cancer is also associated with enhanced progression-free survival (PFS) from Zejula™ (niraparib) maintenance therapy.

Learn More

Recommended Links